Final Witness Steps Down in History's Costliest UK Inquiry
The UK COVID-19 inquiry closed its final day of witness testimony this week after four years and £200 million — making it the most expensive public inquiry in British history. Baroness Heather Hallett, the inquiry chair, defended both the timeline and the cost, calling completion in under four years "an achievement" despite mounting criticism over the price tag.
Matt Fowler, co-founder of COVID-19 Bereaved Families for Justice UK, said the inquiry left "government incompetence, chaos and callousness" on the public record. "This hard-hitting, clear-sighted and damning inquiry absolutely has been worth it," Fowler said, urging officials to use the findings as a blueprint "to take brave, decisive, urgent action." But he warned: the country remains unprepared for the next crisis.
NHS 'Superhuman Efforts' Masked System Failure
The inquiry's latest findings on the NHS delivered a stark verdict: the health service "teetered on the brink of collapse" and only avoided it through the "almost superhuman efforts" of staff. Hallett rejected claims by Conservative ministers at the time that the NHS had not been overwhelmed. "Healthcare systems coped, but only just," she said — language that matters deeply to bereaved families who watched loved ones die in overwhelmed wards.
For prediction market traders tracking government accountability and public health preparedness, the inquiry's conclusions offer a baseline for pricing future pandemic response scenarios. The findings confirm long-standing concerns about NHS capacity, care quality, and political choices — factors that could move markets on healthcare infrastructure bets and government approval ratings. Fowler's warning that the UK remains unprepared suggests ongoing vulnerability that traders should factor into long-tail risk assessments.
What Comes Next
With witness testimony complete, the inquiry now moves to its final report phase. The question for markets: will the £200 million investment translate into concrete policy changes, or will it join the long list of expensive inquiries that gather dust? Bereaved families are watching — and so should anyone betting on UK resilience in the next health crisis.